Ballaststoffe und Intervallausdauertraining – 2 Strategien zur Verbesserung von MASLD, Adipositas und kardiometabolischer Gesundheit

Deleted Journal, Год журнала: 2025, Номер unknown

Опубликована: Фев. 25, 2025

---

MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women

Biomedicines, Год журнала: 2025, Номер 13(4), С. 855 - 855

Опубликована: Апрель 2, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic influenced by genetic, lifestyle, and environmental factors. While MASLD more prevalent in men, women are at increased risk after menopause, highlighting critical pathogenetic role of sex hormones. The complex interplay between estrogen deficiency, visceral fat accumulation, metabolic syndrome (MetS), inflammation accelerates progression, increases cardiovascular (CV) risk, triggers a cycle worsening adiposity, dysfunction, psychological problems, including eating disorders. Weight loss postmenopausal can significantly improve both outcomes, helping to prevent related conditions. This review examines prevalence MASLD, its comorbidities (type 2 diabetes T2D, CV, mental disorders), mechanisms, pharmacological treatment with GLP-1 receptor agonists (GLP1-RAs), focus on women. Given use GLP1-RAs obesity T2D patients, increase MetS this analyzes potential stable GLP-1–estrogen conjugate as therapeutic approach subgroup. By combining synergistic effects hormones, dual agonist has been shown food intake reward suppression, resulting greater weight improved insulin sensitivity, glucose, lipid metabolism. Therefore, we hypothesize that pharmacotherapy may provide targeted benefits than either hormone alone protecting liver, β-cells, overall health. As these only supported preclinical data, highlights need for future research evaluate confirm mechanisms efficacy clinical settings, particularly

Язык: Английский

---

Global, Regional, and National Temporal Trend and Patterns of Change in the Burden of Asthma From 1990 to 2021: An Analysis of the Global Burden of Disease Study 2021

Clinical and Experimental Pharmacology and Physiology, Год журнала: 2025, Номер 52(5)

Опубликована: Апрель 5, 2025

ABSTRACT Background Asthma presents a significant challenge to the global healthcare systems and imposes heavy socioeconomic burden. Previous studies had geographical limitations lacked comprehensive analysis. The study utilises data from 2021 Global Burden of Disease ( GBD ) assess global, regional, national burden asthma 1990 2021. It examines disease trends, highlights health inequalities aims provide scientific evidence for future public strategies optimisation resource allocation. Methods Data were used estimate incidence, prevalence, mortality, disability‐adjusted life years (DALYs) across 21 regions 204 countries territories Temporal trends analysed, relationship between socio‐demographic index (SDI) was examined using smoothing spline model. Analyses included slope inequality concentration disparities, frontier analysis achievable outcomes based on development levels, decomposition identify drivers changes in DALYs number. Results Over past three decades, age‐standardised has declined, with mortality DALY rates decreasing by 46% 44%, respectively. However, absolute number deaths increased 17%, particularly among females, especially low low‐middle SDI regions. Significant persist, high‐SDI benefiting better control, while low‐SDI face disproportionate burdens due disparities. Frontier gaps current optimal require investment control. Aging, population growth, epidemiological are key trends. High body mass (BMI) remains leading risk factor, smoking occupational exposures continue contribute significantly. Conclusions yet regional disparities experiencing higher limited access environmental risks. BMI, remain contributors, requiring targeted interventions lifestyle modifications.

Язык: Английский

---

Metabolic diseases in the East Asian populations

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 8, 2025

Язык: Английский

---

Glucagon-like-peptide 1 receptor agonist for metabolic dysfunction-associated steatotic liver disease: hype or hope?

Singapore Medical Journal, Год журнала: 2025, Номер 66(4), С. 173 - 174

Опубликована: Апрель 1, 2025

Язык: Английский

---